Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab

PURPOSE: Antivascular endothelial growth factor injection is the mainstay of treating neovascular age-related macular degeneration (AMD). Previous studies have shown that switching treatment from ranibizumab to aflibercept led to an improvement in eyes with recalcitrant activity. Herein, we identify...

Descripción completa

Detalles Bibliográficos
Autores principales: Nudleman, Eric, Wolfe, Jeremy D, Woodward, Maria A, Yonekawa, Yoshihiro, Williams, George A, Hassan, Tarek S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4907716/
https://www.ncbi.nlm.nih.gov/pubmed/27354759
http://dx.doi.org/10.2147/OPTH.S109894

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4907716/
https://www.ncbi.nlm.nih.gov/pubmed/27354759
http://dx.doi.org/10.2147/OPTH.S109894

Ejemplares similares